tau蛋白、胶质纤维状酸性蛋白及抗β2糖蛋白1抗体水平与高血压脑出血患者预后的相关性分析

Analysis on correlation of tau protein,glial fibrillary acidic protein,and anti-β2 glycoprotein 1 antibody levels with prognosis in patients with hypertensive intracerebral hemorrhage

目的分析tau蛋白、胶质纤维状酸性蛋白(glial fibrillary acidic protein,GFAP)以及抗β2糖蛋白1抗体(anti-β2 glycoprotein 1 antibody,aβ2-GP1)水平与高血压脑出血(hypertensive intracerebral hemorrhage,HICH)患者预后的相关性。方法将70例HICH患者纳入研究组,另将同时期进行健康体检的70例人员纳入对照组。比较两组tau蛋白、GFAP以及aβ2-GP1水平。比较不同预后HICH患者tau蛋白、GFAP、aβ2-GP1水平和美国国立卫生院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分;并分析HICH患者相关指标与NIHSS评分的相关性。使用受试者工作特征(receiver operation characteristic,ROC)曲线分析相关指标预测HICH患者不良预后的临床价值。结果与对照组比较,观察组tau蛋白、GFAP以及aβ2-GP1水平均较高(P<0.05)。预后不良的HICH患者tau蛋白、GFAP、aβ2-GP1水平和NIHSS评分均较高(P<0.05);相关指标与NIHSS评分均呈正相关(均P<0.05)。相关指标预测HICH患者预后不良的最佳临界值:tau蛋白≥258.15ng/L、GFAP≥16.15ng/L、aβ2-GP1≥18.35 RU/mL,此时ROC曲线下面积(area under the curve,AUC)为0.908(95%CI:0.828~0.988,P<0.05)、0.871(95%CI:0.781~0.961,P<0.05)、0.839(95%CI:0.728~0.949,P<0.05),敏感度为77.27%、77.27%、72.73%,特异度为97.92%、85.42%、89.58%。结论HICH患者tau蛋白、GFAP以及aβ2-GP1水平较高,神经损伤较重、预后不良的HICH患者相关指标更高,监测HICH患者tau蛋白、GFAP以及aβ2-GP1水平可用于不良预后的评估。

Objective To analyze the correlation between tau protein,glial fibrillary acidic protein(GFAP),and anti-β2 glycoprotein 1 antibody(aβ2-GP1)levels and the prognosis of patients with hypertensive intracerebral hemorrhage(HICH).Methods Seventy patients with HICH were included in observation group,and another 70 healthy individuals undergoing physical examinations during the same period were included in the control group.The levels of tau protein,GFAP,and aβ2-GP1 were compared between the two groups.The levels of tau protein,GFAP,aβ2-GP1,and the National Institutes of Health Stroke Scale(NIHSS)scores were compared between HICH patients with different prognoses,and their correlations were analyzed.Receiver operating characteristic(ROC)curve analysis was used to evaluate the clinical value of relevant indicators in predicting poor prognosis in HICH patients.Results Compared with the control group,the levels of tau protein,GFAP,and aβ2-GP1 were significantly higher in the observation group(P<0.05).Patients with poor prognosis had higher levels of tau protein,GFAP,aβ2-GP1,and NIHSS scores(P<0.05).All relevant indicators were positively correlated with NIHSS scores(all P<0.05).The optimal cut-off values for predicting poor prognosis in HICH patients were tau protein≥258.15 ng/L,GFAP≥16.15 ng/L,and aβ2-GP1≥18.35 RU/mL,with areas under the curve(AUCs)of 0.908(95%CI:0.828-0.988,P<0.05),0.871(95%CI:0.781-0.961,P<0.05),and 0.839(95%CI:0.728-0.949,P<0.05),respectively.The sensitivity was 77.27%,77.27%,and 72.73%,and the specificity was 97.92%,85.42%,and 89.58%,respectively.Conclusions Patients with HICH exhibit elevated levels of tau protein,GFAP,and aβ2-GP1,indicating more severe neurological damage.Patients with poor prognosis have even higher levels of these indicators.Monitoring the levels of these biomarkers can be used to assess the poor prognosis of HICH patients.